UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2025
Commission File Number: 002-023311
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
______________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
On February 13, 2025, Ascentage Pharma Group International issued a Hong Kong Stock Exchange announcement entitled “CLOSING OF PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION IN RELATION TO THE OFFERING OF AMERICAN DEPOSITARY SHARES”.
A copy of the Hong Kong Stock Exchange announcement is attached as Exhibit 99.1 to this Form 6-K and is incorporated by reference herein.
INDEX TO EXHIBITS
| Exhibit | |
| Number | Exhibit Title |
| 99.1 | Hong Kong Stock Exchange Announcement dated February 13, 2025 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ASCENTAGE PHARMA GROUP INTERNATIONAL | |
| Date: February 13, 2025 | /s/ Dajun Yang |
| Name: Dajun Yang | |
| Title: Chief Executive Officer |
